Fluvoxamine treatment of generalized social anxiety disorder in Japan : a randomized double-blind, placebo-controlled study

Asakura, Satoshi; Tajima, Osamu; Koyama, Tsukasa

Fluvoxamine treatment of generalized social anxiety disorder in Japan : a randomized double-blind, placebo-controlled study

Asakura, Satoshi; Tajima, Osamu; Koyama, Tsukasa

The International Journal of Neuropsychopharmacology, 2007, 10(2), 263-274

Permalink : https://hdl.handle.net/2115/33762

このアイテムのアクセス数:3,435件（2026-08-12 18:50 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
S1461145706006602a	pdf	125 KB	2,805

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/33762
タイトル	Fluvoxamine treatment of generalized social anxiety disorder in Japan : a randomized double-blind, placebo-controlled study
著者	Asakura, Satoshi ; Tajima, Osamu ; Koyama, Tsukasa
著者名 Asakura, Satoshi
著者名 Tajima, Osamu
著者名 Koyama, Tsukasa
言語	英語
キーワード	Fluvoxamine maleate
	generalized social anxiety disorder (GSAD)
	Liebowitz Social Anxiety Scale–Japanese Version (LSAS-J)
	placebo-controlled double-blind study
	selective serotonin reuptake inhibitor (SSRI)
発行日	2007-04
出版者	Cambridge University Press
収録物名	The International Journal of Neuropsychopharmacology
巻(号)	10(2)
ページ	263-274
抄録	The efficacy of selective serotonin reuptake inhibitors (SSRIs) for the treatment of social anxiety disorder (SAD) has been reported in the USA and Europe. However, no clinical investigation has been done with SSRIs in Japanese patients with SAD. This study was performed to determine the effectiveness and safety of fluvoxamine for generalized SAD (GSAD) in Japanese patients. In this double-blind study, patients meeting DSM-IV criteria for GSAD were randomized to receive treatment with fluvoxamine or placebo for 10wk. Fluvoxamine treatment was initiated at 50mg/d, and increased by 50mg weekly to a maximum of 150 or 300mg/d. The primary efficacy outcome was mean change from baseline on the Liebowitz Social Anxiety Scale–Japanese Version (LSAS-J) total score. The secondary outcomes were response according to the Clinical Global Impressions–Global Improvement (CGI-I) score and three domains of the Sheehan Disability Scale (SDS; used to assess psychosocial impairment). A total of 176 fluvoxamine-treated patients and 89 placebo-treated patients were eligible for the efficacy analysis. At week 10, the fluvoxamine-treated patients had a significantly greater reduction in the LSAS-J total score compared with placebo-treated patients (p=0.0197), with significantly more fluvoxamine recipients being at least much improved on the CGI-I scale compared with placebo-treated patients (p=0.024). Fluvoxamine-treated patients also had better responses on the SDS compared with placebo-treated patients (p=0.0208). Fluvoxamine was safe and well tolerated. These results suggest that fluvoxamine is effective for the treatment of Japanese patients with GSAD.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Copyright © 2006 Collegium Internationale Neuropsychopharmacologicum
PISSN	1461-1457
EISSN	1469-5111
関連情報	PMID 16573847
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1017/S1461145706006602